Inovio Pharmaceuticals (INO) Rating Lowered to Strong Sell at BidaskClub

BidaskClub cut shares of Inovio Pharmaceuticals (NASDAQ:INO) from a sell rating to a strong sell rating in a report issued on Saturday.

A number of other analysts also recently issued reports on INO. Citigroup initiated coverage on shares of Inovio Pharmaceuticals in a report on Friday, October 6th. They set a buy rating and a $10.00 price target on the stock. HC Wainwright set a $13.00 price target on shares of Inovio Pharmaceuticals and gave the stock a buy rating in a report on Friday, October 6th. Zacks Investment Research downgraded shares of Inovio Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, October 10th. Royal Bank of Canada initiated coverage on shares of Inovio Pharmaceuticals in a report on Wednesday, October 18th. They set an outperform rating and a $11.00 price target on the stock. Finally, ValuEngine downgraded shares of Inovio Pharmaceuticals from a sell rating to a strong sell rating in a report on Thursday, November 9th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating to the company. Inovio Pharmaceuticals has an average rating of Hold and a consensus target price of $19.16.

Shares of Inovio Pharmaceuticals (INO) opened at $4.10 on Friday. Inovio Pharmaceuticals has a twelve month low of $4.09 and a twelve month high of $9.86. The stock has a market cap of $370.21, a price-to-earnings ratio of -3.47 and a beta of 2.54.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.15). Inovio Pharmaceuticals had a negative return on equity of 72.19% and a negative net margin of 221.55%. The firm had revenue of $2.60 million for the quarter, compared to analysts’ expectations of $10.27 million. During the same period last year, the company posted ($0.28) earnings per share. The business’s quarterly revenue was down 79.2% on a year-over-year basis. analysts anticipate that Inovio Pharmaceuticals will post -1.12 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the company. BlueCrest Capital Management Ltd acquired a new stake in shares of Inovio Pharmaceuticals in the second quarter valued at about $107,000. Virginia Retirement Systems ET AL acquired a new stake in shares of Inovio Pharmaceuticals in the third quarter valued at about $101,000. Neuberger Berman Group LLC acquired a new stake in shares of Inovio Pharmaceuticals in the third quarter valued at about $115,000. Engineers Gate Manager LP acquired a new stake in shares of Inovio Pharmaceuticals in the third quarter valued at about $117,000. Finally, Emerald Advisers Inc. PA raised its position in shares of Inovio Pharmaceuticals by 84.0% in the third quarter. Emerald Advisers Inc. PA now owns 20,323 shares of the biopharmaceutical company’s stock valued at $129,000 after buying an additional 9,280 shares during the last quarter. Institutional investors and hedge funds own 32.10% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be accessed at https://www.com-unik.info/2018/02/06/inovio-pharmaceuticals-ino-rating-lowered-to-strong-sell-at-bidaskclub.html.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit